• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Case Western Reserve University receives $1.5M grant from Foundation Fighting Blindness to test possible new treatment for inherited retinal disease

by
July 8, 2024
in Health
Reading Time: 2 mins read
0
Shigemi Matsuyama
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

CLEVELAND—There’s only one U.S. Food and Drug Administration-approved therapy for an inherited retinal disease, and dozens of retinitis pigmentosa (RP) genes for which no therapy is available.

Shigemi Matsuyama

Credit: Case Western Reserve University

CLEVELAND—There’s only one U.S. Food and Drug Administration-approved therapy for an inherited retinal disease, and dozens of retinitis pigmentosa (RP) genes for which no therapy is available.

With a new three-year, $1.5 million grant from the Foundation Fighting Blindness, Shigemi Matsuyama, an associate professor of ophthalmology and visual sciences at the Case Western Reserve University School of Medicine, will test a possible breakthrough drug that can be taken by mouth—one that may address many RP disease manifestations, regardless of the underlying genetic mutation.

“We believe it can serve as the basis of an oral medicine to prevent blindness in RP patients, regardless of the underlying gene mutations,” Matsuyama said.

The disease…and promising science

RP causes blindness when cells in the retina that respond to light—called photoreceptors—die.

In a previous foundation-funded drug discovery program from 2017-20, Matsuyama and his research team developed a series of novel orally-active cell-death inhibitors—known as Cytoprotective Small Compounds (CPSCs)—which work by blocking the activation of Bax, a protein that contributes to cell death. Their lead compound prevented retinal cell death and vision loss in four mouse models of inherited retinal disease.

The proposed studies, which include toxicology evaluation and drug-formulation testing—for both oral drugs and eye drops—are aimed at advancing the technology to U.S. Food and Drug Administration (FDA)-regulated clinical trials.

“Our primary objective is bringing an CPSC-based therapeutic to RP patients who are suffering from the fear of blindness,” Matsuyama said.

Bax-induced cell death is also a major cause of various neurodegenerative conditions, including glaucoma, ischemia-reperfusion injury, amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

“Therefore,” he said, “there is significant potential to expand the application of our Bax-inhibiting therapeutic for additional uses.”

“The Foundation Fighting Blindness is proud to support Dr. Shigemi Matsuyama’s research,” said Chad Jackson, senior director of preclinical translational research at the foundation. “Through this award, we continue our commitment to advancing scientific discoveries that have the potential to realize tangible solutions for those affected by inherited retinal diseases.”

About the Foundation Fighting Blindness

The foundation is focused on treating and curing blindness caused by the spectrum of blinding retinal diseases including: RP, macular degeneration and Usher syndrome.

                                                            ### 

Case Western Reserve University is one of the country’s leading private research institutions. Located in Cleveland, we offer a unique combination of forward-thinking educational opportunities in an inspiring cultural setting. Our leading-edge faculty engage in teaching and research in a collaborative, hands-on environment. Our nationally recognized programs include arts and sciences, dental medicine, engineering, law, management, medicine, nursing and social work. About 6,200 undergraduate and 6,100 graduate students comprise our student body. Visit case.edu to see how Case Western Reserve thinks beyond the possible.



Share12Tweet8Share2ShareShareShare2

Related Posts

Diabetic Patients in Upper Egypt: Adherence and Perception Insights

October 2, 2025

Movement Skills Boost Executive Function in Autistic Kids

October 2, 2025

Mayo Clinic Secures Up to $40 Million from ARPA-H to Advance Groundbreaking Air Safety Research

October 2, 2025

Early Onset of Neuroinflammation Observed in Individuals with Down Syndrome

October 2, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    92 shares
    Share 37 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    82 shares
    Share 33 Tweet 21
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Diabetic Patients in Upper Egypt: Adherence and Perception Insights

Movement Skills Boost Executive Function in Autistic Kids

Mayo Clinic Secures Up to $40 Million from ARPA-H to Advance Groundbreaking Air Safety Research

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.